Sex: F
Vaccine: HEP, HEP, HEP
Symptoms: Accidental underdose, Inappropriate schedule of product administration, Product administered to patient of inappropriate age, Underdose
Clinical narrative: Wrong dose/accidentally administered with pediatric doses of Engerix-B; adult patients were accidentally administered with pediatric doses of Engerix-B; Drug dose administration interval too long; Wrong dose/accidentally administered with pediatric doses of Engerix-B; adult patients were accidentally administered with pediatric doses of Engerix-B; Wrong dose/accidentally administered with pediatric doses of Engerix-B; adult patients were accidentally administered with pediatric doses of Engerix-B; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of accidental underdose in a 60-year-old female patient who received HBV (Engerix B pediatric) (batch number 9K74F, expiry date 27-OCT-2025) for prophylaxis.   Co-suspect products included HBV (Engerix B pediatric) (batch number 9K74F, expiry date 27-OCT-2025) for prophylaxis and HBV (Engerix B pediatric) (batch number 9K74F, expiry date 27-OCT-2025) for prophylaxis.   On 28-JUL-2024, the patient received the 3rd dose of Engerix B pediatric. On 06-JAN-2024, the patient received the 2nd dose of Engerix B pediatric. On 01-DEC-2023, the patient received the 1st dose of Engerix B pediatric. On 01-DEC-2023, not applicable after receiving Engerix B pediatric and Engerix B pediatric and an unknown time after receiving Engerix B pediatric, the patient experienced accidental underdose (Verbatim: Wrong dose/accidentally administered with pediatric doses of Engerix-B) and adult use of a child product (Verbatim: adult patients were accidentally administered with pediatric doses of Engerix-B). On 06-JAN-2024, the patient experienced accidental underdose (Verbatim: Wrong dose/accidentally administered with pediatric doses of Engerix-B) and adult use of a child product (Verbatim: adult patients were accidentally administered with pediatric doses of Engerix-B). On 28-JUL-2024, the patient experienced accidental underdose (Verbatim: Wrong dose/accidentally administered with pediatric doses of Engerix-B), adult use of a child product (Verbatim: adult patients were accidentally administered with pediatric doses of Engerix-B) and drug dose administration interval too long (Verbatim: Drug dose administration interval too long). The outcome of the accidental underdose, adult use of a child product, accidental underdose, adult use of a child product, accidental underdose and adult use of a child product were unknown and the outcome of the drug dose administration interval too long was not reported.   Additional Information: GSK Receipt Date: 15-AUG-2024 The pharmacist reported that the adult patient was accidentally administered with pediatric doses of Engerix B, which led to accidental underdose and adult use of achild product. The patient received 3 Engerix-B doses so far, all the 3 off them were pediatric.  The lot number and expiration date for lot number of second dose are not asked by the agent on first call, but after a call back, agent clarified that second dose was the same lot number of pediatric dose 9K74F. The patient received 3rd dose of Engerix B vaccine, later than the recommended interval, which led to lengthening of vaccination schedule. This case had been linked with US2024AMR103610, reported by the same reporter.; Sender's Comments:  US-GSK-US2024AMR103610:2nd case for another two patient